Page 54 - pdf_publisher2

10. Biondi B., Palmieri EA., Klain M., Schlumberger M., Filetti S.,Lombardi G. Subclinical hyper'thyroidism: clinical fea' tures and treatment options. //Eur J Endocrinol. 2005 Jan;152(1):1'9.

11. Burgi H., Therapy of euthyroid goiter. //Schweiz Med Wochenschr. 1988 Dec 17;118(50):1881'5.

12. Castro MR., Caraballo PJ., Morris JC., Effectiveness of thy' roid hormone suppressive therapy in benign solitary thyroid nodules: a meta'analysis.

13. Bononi M., Tocchi A., Cangemi V., Vecchione A., Gio' vagnoli MR., De Cesare A., Fiori E., Volpino P., Brozzetti S., Meucci M., Scozzafava S. Lymph node dissection in papillary or fol'licular thyroid carcinoma. //Anticancer Res. 2004 Jul' Aug;24(4):2439'42.

14. Crile G Jr., Antunez AR., Esselstyn CB Jr., Hawk WA., Skillern PG. The advantages of subto'tal thyroidectomy and suppression of TSH in the primary treatment of papillary car' cinoma of the thyroid. //Cancer. 1985 Jun 1;55(11):2691'7. 15. Fazio S., Biondi B., Carella C., Sabatini D., Cittadini A., Panza N., Lombardi G., Sacca L. Dia'stolic dysfunction in patients on thyroid'stimulating hormone suppressive therapy with levothy'roxine: beneficial effect of beta'blockade. //J Clin Endocrinol Metab. 1995 Jul;80(7):2222'6.

16. Francia G., Davi MV., Petroziello A., Sussi PL. Hormonal therapy in differentiated carcinoma of the thyroid gland. //Chir Ital. 1994;46(4):56'8.

17. Fujiyama K., Kiriyama T., Ito M., Kimura H., Ashizawa K., Tsuruta M., Nagayama Y., Villa'dolid MC., Yokoyama N., Nagataki S. Suppressive doses of thyroxine do not accelerate age'related bone loss in late postmenopausal women. //Thy' roid. 1995 Feb;5(1):13'7.

18. Kang DG, Oh H, Chung HT, Lee HS. Inhibition of angiotensin converting enzyme by lithos'permic acid B isolat' ed from Radix Salviae miltiorrhiza Bunge. //Phytother Res. 2003 Sep;17(8):917'20.

19. Khanna CM., Dubey YS., Shankar R., Kaur G. Effects of long'term thyroid hormone suppres'sive treatment on the cardiac functions. //Indian Heart J. 1997 May' Jun;49(3):289'92.

20. Koc M., Ersoz HO., Akpinar I., Gogas'Yavuz D., Deyneli O., Akalin S. Effect of low' and high'dose levothyroxine on thyroid nodule volume: a crossover placebo'controlled trial. //Clin Endocrinol (Oxf). 2002 Nov;57(5):621'8.

21. Kowalczyk P, Sielanczyk A, Nowak J, Matuszewska G, Roskosz J, Czernik E, Gubala E, Jar'zab B Effects of L'thy' roxine suppressive therapy on cardiac mass in patients with differenti'ated thyroid cancer. //Pol Arch Med Wewn. — 2001 Feb;105(2):123'30.

22. Komlos L., Shimberg R., Halbrecht I., Zohar Y., Strauss M., Laurian L., Laurian N. Primary tissue cultures of benign and malignant human thyroid tumors: effect of TSH. //Otolaryn' gol Head Neck Surg. 1988 Jul;99(1):10'5.

23. Krouse RS., McCarty T., Weiss LM., Wagman LD., Postop' erative suppressive therapy for thy'roid adenomas. //Am Surg. 2000 Aug;66(8):751'5.

24. Kung AW., Lorentz T., Tam SC. Thyroxine suppressive ther' apy decreases bone mineral den'sity in post'menopausal women. //Clin Endocrinol (Oxf). 1993 Nov;39(5):535'40. 25. Lacka K. Treatment with L'thyroxine for differentiated thy' roid carcinoma. //Wiad Lek. 2001;54 Suppl 1:368'72. 26. Marcocci C., Golia F., Bruno'Bossio G., Vignali E., Pinchera A. Carefully monitored levothy'roxine suppressive therapy is not associated with bone loss in premenopausal women. //J Clin Endocrinol Metab. 1994 Apr;78(4):818'23. 27. Mazziotti G., Sorvillo F., Piscopo M., Cioffi M., Pilla P., Biondi B., Iorio S., Giustina A., Amato G., Carella C. Recombinant human TSH modulates in vivo C'telopeptides of type'1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women moni' tored for differentiated thyroid carcinoma. //J Bone Miner Res. 2005 Mar;20(3):480'6. Epub 2004 Nov 29.

28. Pujol P., Daures JP., Nsakala N., Baldet L., Bringer J., Jaffi' ol C. Degree of thyrotropin sup'pression as a prognostic determinant in differentiated thyroid cancer. //J Clin Endocrinol Metab. 1996 Dec;81(12):4318'23.

29. Radetti G., Castellan C., Tato L., Platter K., Gentili L., Adami S. Bone mineral density in chil'dren and adolescent females treated with high doses of L'thyroxine. //Horm Res. 1993;39(3'4):127'31

30. Razack MS., Shimaoka K., Sako K., Rao U. Suppressive therapy of thyroid nodules in patients with previous radiother' apy to the head and neck. //Am J Surg. 1988 Oct;156(4):290' 3.

31. Shapiro LE., Sievert R., Ong L., Ocampo EL., Chance RA., Lee M., Nanna M., Ferrick K., Surks MI. Minimal cardiac effects in asymptomatic athyreotic patients chronically treat' ed with thyrotropin'suppressive doses of L'thyroxine. //J Clin Endocrinol Metab. 1997 Aug;82(8):2592'5.

32. Sijanovic S., Karner I. Bone loss in premenopausal women on long'term suppressive therapy with thyroid hormone. //Med' scape Womens Health. 2001 Oct;6(5):3.

33. Welker MJ., Orlov D. Thyroid nodules. //Am Fam Physician. 2003 Feb 1;67(3):559'66.

34. Winterhoff H, Gumbinger HG, Vahlensieck U, Kemper FH, Schmitz H, Behnke B Endocrine effects of Lycopus europaeus L. following oral application. //Arzneimit' telforschung. 1994 Jan;44(1):41'5,

35. Zelmanovitz F., Genro S., Gross JL., Suppressive therapy with levothyroxine for solitary thy'roid nodules: a double' blind controlled clinical study and cumulative meta'analyses. //J Clin En'docrinol Metab. 1998 Nov;83(11):3881'5.

Page 54 - pdf_publisher2_project

Page 54 - pdf_publisher2_project